Skip to main content

Table 1 Population characteristics

From: Artificial intelligence for reduced dose 18F-FDG PET examinations: a real-world deployment through a standardized framework and business case assessment

Patient characteristics Number (%) [N = 61]
 Male 25 (40.9%)
 Female 36 (59.1%)
 PET scanner 1 (GE Discovery ST-4) 20 (32.8%)
 PET scanner 2 (GE Discovery ST-16) 21 (34.4%)
 PET scanner 3 (GE Discovery IQ) 20 (32.8%)
Tumor characteristics
 Rectal-colon cancer 13 (21.3%)
 Lung cancer 13 (21.3%)
 Hodgkin/non-Hodgkin lymphoma 9 (14.8%)
 Gynecological cancer 8 (13.1%)
 Breast cancer 8 (13.1%)
 Melanoma 4 (6.6%)
 Pancreatic cancer 2 (3.3%)
 Gastric cancer 2 (3.3%)
 Cholangiocarcinoma 1 (1.6%)
 Head and neck cancer 1 (1.6%)
  Median (range)
Age 66 years (33-84)
Body weight 67 kg (40-100)
Dose injected (study protocol) 131 MBq (99-199)
Reference dose (standard procedure)a 196 MBq (148-296)
  1. aThese values represent the routine administered dose of 18F-FDG according to the institutional standard of care procedures